
Teplizumab and the Evolving Landscape of Type 1 Diabetes Immunotherapy: From Delay to Prevention and Beyond
Abstract Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas. For decades, management has focused on exogenous insulin administration to control blood glucose levels. The […]